140 related articles for article (PubMed ID: 33652084)
1. KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo.
Jungwirth G; Yu T; Cao J; Eddine MA; Moustafa M; Warta R; Debus J; Unterberg A; Abdollahi A; Herold-Mende C
Cancer Lett; 2021 May; 506():1-10. PubMed ID: 33652084
[TBL] [Abstract][Full Text] [Related]
2. Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer.
Purcell JW; Davis J; Reddy M; Martin S; Samayoa K; Vo H; Thomsen K; Bean P; Kuo WL; Ziyad S; Billig J; Feiler HS; Gray JW; Wood KW; Cases S
Clin Cancer Res; 2010 Jan; 16(2):566-76. PubMed ID: 20068098
[TBL] [Abstract][Full Text] [Related]
3. KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain?
Valensin S; Ghiron C; Lamanna C; Kremer A; Rossi M; Ferruzzi P; Nievo M; Bakker A
BMC Cancer; 2009 Jun; 9():196. PubMed ID: 19545421
[TBL] [Abstract][Full Text] [Related]
4. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
Carol H; Lock R; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
Pediatr Blood Cancer; 2009 Dec; 53(7):1255-63. PubMed ID: 19554570
[TBL] [Abstract][Full Text] [Related]
5. Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer.
Martens-de Kemp SR; Nagel R; Stigter-van Walsum M; van der Meulen IH; van Beusechem VW; Braakhuis BJ; Brakenhoff RH
Clin Cancer Res; 2013 Apr; 19(8):1994-2003. PubMed ID: 23444224
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers.
Murase Y; Ono H; Ogawa K; Yoshioka R; Ishikawa Y; Ueda H; Akahoshi K; Ban D; Kudo A; Tanaka S; Tanabe M
Cancer Sci; 2021 Nov; 112(11):4641-4654. PubMed ID: 34510663
[TBL] [Abstract][Full Text] [Related]
7. Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma.
Gampa G; Kenchappa RS; Mohammad AS; Parrish KE; Kim M; Crish JF; Luu A; West R; Hinojosa AQ; Sarkaria JN; Rosenfeld SS; Elmquist WF
Sci Rep; 2020 Apr; 10(1):6524. PubMed ID: 32300151
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Id1-Kif11 Axis in Triple-Negative Breast Cancer Using Combination Therapy.
Thankamony AP; Murali R; Karthikeyan N; Varghese BA; Teo WS; McFarland A; Roden DL; Holliday H; Konrad CV; Cazet A; Dodson E; Yang J; Baker LA; George JT; Levine H; Jolly MK; Swarbrick A; Nair R
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32911668
[TBL] [Abstract][Full Text] [Related]
9. Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma.
Nakano T; Fujimoto K; Tomiyama A; Takahashi M; Achiha T; Arita H; Kawauchi D; Yasukawa M; Masutomi K; Kondo A; Narita Y; Maehara T; Ichimura K
Cancer Sci; 2022 Feb; 113(2):697-708. PubMed ID: 34839570
[TBL] [Abstract][Full Text] [Related]
10. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.
LoRusso PM; Goncalves PH; Casetta L; Carter JA; Litwiler K; Roseberry D; Rush S; Schreiber J; Simmons HM; Ptaszynski M; Sausville EA
Invest New Drugs; 2015 Apr; 33(2):440-9. PubMed ID: 25684345
[TBL] [Abstract][Full Text] [Related]
11. Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition.
Gupta V; Samuleson CG; Su S; Chen TC
Neurosurg Focus; 2007; 23(4):E9. PubMed ID: 17961046
[TBL] [Abstract][Full Text] [Related]
12. Identification of KIF11 As a Novel Target in Meningioma.
Jungwirth G; Yu T; Moustafa M; Rapp C; Warta R; Jungk C; Sahm F; Dettling S; Zweckberger K; Lamszus K; Senft C; Loehr M; Keßler AF; Ketter R; Westphal M; Debus J; von Deimling A; Simon M; Unterberg A; Abdollahi A; Herold-Mende C
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30991738
[TBL] [Abstract][Full Text] [Related]
13. The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.
Hernández-García S; San-Segundo L; González-Méndez L; Corchete LA; Misiewicz-Krzeminska I; Martín-Sánchez M; López-Iglesias AA; Algarín EM; Mogollón P; Díaz-Tejedor A; Paíno T; Tunquist B; Mateos MV; Gutiérrez NC; Díaz-Rodriguez E; Garayoa M; Ocio EM
Haematologica; 2017 Dec; 102(12):2113-2124. PubMed ID: 28860344
[TBL] [Abstract][Full Text] [Related]
14. Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro.
Ragel BT; Gillespie DL; Kushnir V; Polevaya N; Kelly D; Jensen RL
Neurosurgery; 2006 Nov; 59(5):1109-20; discussion 1120-1. PubMed ID: 17143245
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
Schrell UM; Rittig MG; Anders M; Kiesewetter F; Marschalek R; Koch UH; Fahlbusch R
J Neurosurg; 1997 May; 86(5):845-52. PubMed ID: 9126901
[TBL] [Abstract][Full Text] [Related]
16. Combined Inhibition of KIF11 and KIF15 as an Effective Therapeutic Strategy for Gastric Cancer.
Sun RF; He N; Zhang GY; Yu ZY; Li LS; Ma ZJ; Jiao ZY
Curr Cancer Drug Targets; 2023; 23(4):293-306. PubMed ID: 35713129
[TBL] [Abstract][Full Text] [Related]
17. The treatment of malignant meningioma with verotoxin.
Salhia B; Rutka JT; Lingwood C; Nutikka A; Van Furth WR
Neoplasia; 2002; 4(4):304-11. PubMed ID: 12082546
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas.
Jungwirth G; Yu T; Liu F; Cao J; Alaa Eddine M; Moustafa M; Abdollahi A; Warta R; Unterberg A; Herold-Mende C
Clin Cancer Res; 2023 Jan; 29(1):233-243. PubMed ID: 36282277
[TBL] [Abstract][Full Text] [Related]
19. Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
Tuchen M; Wilisch-Neumann A; Daniel EA; Baldauf L; Pachow D; Scholz J; Angenstein F; Stork O; Kirches E; Mawrin C
Eur J Cancer; 2017 Mar; 73():9-21. PubMed ID: 28082204
[TBL] [Abstract][Full Text] [Related]
20. Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide.
Spear SA; Burns SS; Oblinger JL; Ren Y; Pan L; Kinghorn AD; Welling DB; Chang LS
Otol Neurotol; 2013 Oct; 34(8):1519-27. PubMed ID: 23928514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
